an XXXX our With of our will and earnings and Thank with I on our you, today strategy, call. an Financial Hombeck, quarter President; Dr. everyone, Sandy followed with a by overview conference our plans Chief first welcome, begin new Sandy Torsten of with financials. operations, execution and update and our to development Torsten are review me our Milligan, Officer.
will open call the for then questions. We
and we year, approximately important the XXX% largest of total this period as we XX% future strategy the for test last volume, to growth than the OvaWatch excited see X,XXX slightly Longitudinal execution rests patients We total Let a Xx Monitoring representing than mass to of that the to to same repeat X.X develop quarter believe now XXXX for testing is grow commercial our it more over with an This by which quarter. as that declined were with Xx by in the me OvaWatch for a tool and begin are first opportunity of X,XXX. an a potentially creating for million offering of that more single-use addressable opportunity masses, year the test. market adnexal multiplying
or risk with to cancer designed payers. available. and the physicians the noninvasive for tool believe avoid other for women physicians is help benefit surgery potentially unnecessary for of something women of which patients, determine the OvaWatch of is will We help adoption OvaWatch benign indeterminant there broad masses, no
In the fact, would in just for more malignancy frontiers of predicting journal in that of than peer-reviewed data have last had used by OvaWatch published showed XXX% and patients. those accuracy Medicine week physician improved
clearly demonstrates women premenopausal health a the a the circulating and drop It incredible host resorted past. causing onset in abrupt near- the utility in Due who physicians have women if to removed, of the offers compared and of but experience that naturally You'll women OvaWatch's let's about and are the accuracy data These an risks. of there gradually. shortly, benefit their hear minute may this of the surgery improve talk malignancy their stop for faced to to hormones long-term surgical about power to assessment ovaries for to risk of menopause menopause paper. and more
physicians adoption and and various with disease, data dementia believe paper Parkinson's a will stakeholders. a driving role women's disease and campaign risk findings increase cardiovascular currently OvaWatch osteoporosis, long-term Surgical central this the payers our play share by few. are and in menopause has been executing name an found to both aggressive to to of We of
of publication testing the month. the periodic saw also this data published Gynecologic supporting We in Oncology peer-reviewed earlier journal,
test over in adnexal is in masses, they of risk The this oncology women the ovarian a offering analysis choose peace OvaWatch will malignancy supports or validation avoid a for cancer low-risk is for of risk and of mind over major as indeterminate XXX the in women masses milestone. to reliable if with physicians women especially surgery journal monitoring time, prestigious a Data of use OvaWatch monitoring well. of gynecologic in
Turning commercial activities. our now to
features more is team of ever Our than prepared advantage expanded OvaWatch. the of take to
with quarter this improve quarter continue XX% to in to when the compared increasing and representative efficiency of to sales year. XXX Our last year volume for full-time first numbers the first
was the strongest despite carried March volume quarter, of territories. In second month was into history, the the and which April, first is company momentum open X month the largest addition, remaining in
with factor first the average to or year. of is the Another for growth $XXX which quarter key full unit was pricing AUP, consistent last quarter, at
we materialized, the volatility of OvaWatch and anticipated the our with at never strong remained margin Importantly, gross launch XX%.
to update Moving on innovation. an
for the research. obtain made new available seeking health development, Milligan. by We Sandy President, of pursuit women's of of administration of including ARPA-H submitted leadership to the month. funds Biden take advantage the the our support and We opportunity for last research to our funding aggressively sources are EndoMDx grants alternative product to OvaMDx grants under
funding The to of submitted be some condensed ARPA-H been been for collaborators. our made have partnership fourth submitted grant decisions expected Other as is applications with which have with grant to portfolio, as the process in quarter. be early
In addition grant Dana by an Farber to NIH submitted Cancer Institute.
only a shown patent proposal may promising drug a in used of solution a and a pairing on a in owns the combined be test that been treatment therapy clinical research. third accurately it for the endometrioma. collaboration noninvasive for the EndoCheck scientific is EndoCheck making grant Our was by identify ARPA-H that has endometrioma, perfect submitted that researcher test included to
noninvasive algorithm. for I simultaneously with women risk, to continue in underinsured as of especially endometrioma, create with the patients. suspected as test that comorbidities the generate validating for an Positioning a income research EndoCheck higher surgical this promise may adolescence manner in believe women tool inexpensive and while EndoCheck
market smart be how we the about to as need of we clinicians to as needs build the However, patients. well meet
conscious extraordinarily where fully would research be spending. all our And deciding fund we are like thoughtful of in of while go. must to We dollars programs, our our we
While we are funding portfolio. on pursuing alternative our focusing of attention EndoCheck, the we are sources for MDx
is will a discipline Now us from the felt training strategic variety who turn Her Dr. expertise, and it tremendous my organization, senior being her sciences month prior the to throughout roles brings relationships. Milligan, providing from has in turn her. years already call ago. clarity leadership incredible just to the refreshing pleasure military, a call Sandy is team. the physician to been joined a a impact as depth with of medical her Sandy to over market-leading the from over life of a insight, She now I a and addition knowledge companies.
